Key result
Targeted therapies like cannabidiol and fenfluramine emerge for the SCN1A channelopathy Dravet syndrome.
Why the study?
Despite advances in molecular genetics enhancing diagnostic precision and targeted therapies, Dravet syndrome carries high morbidity and mortality, making comprehensive multidisciplinary care essential.
This review provides a comprehensive overview of the pathophysiology, clinical spectrum, and emerging therapeutic strategies for Dravet syndrome.
Encourages early genetic diagnosis and targeted therapy in Dravet syndrome; extends foundation for precision medicine research in epilepsy.
Early-onset protracted febrile seizures that progress to drug-resistant epilepsy with neurodevelopmental damage are the hallmarks of Dravet syndrome (DS), a rare, severe developmental and epileptic encephalopathy. First described in 1978, DS is now recognized as a genetic channelopathy predominantly caused by pathogenic variants in the SCN1A gene. The disorder carries significant morbidity and mortality, including a high risk of status epilepticus and sudden unexpected death in epilepsy (SUDEP). Advances in molecular genetics have enhanced diagnostic precision and enabled targeted therapeutic approaches such as cannabidiol and fenfluramine. Despite these advances, comprehensive multidisciplinary care remains essential. This review provides a detailed discussion of epidemiology, molecular mechanisms, clinical progression, diagnostic challenges, management strategies, complications, prognosis, and future directions in Dravet syndrome.
No takes yet. Share an insight, caveat, or question.
Gayathri R. (2026) studied this question. Dravet syndrome is a severe genetic channelopathy predominantly caused by SCN1A variants, where molecular advances have enabled targeted therapies such as cannabidiol and fenfluramine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: